Ichinose M, et al. - Researchers present the results of this prespecified analysis of data from the DYNAGITO study, wherein, the efficacy and safety of tiotropium and olodaterol combination therapy (TIO+OLO 5/5 μg) was compared with that of tiotropium monotherapy (TIO 5 μg) for attenuating moderate-to-severe exacerbations of COPD. The population studied comprised patients with a diagnosis of COPD with at least one moderate-to-severe exacerbation in the previous 12 months. Findings revealed a greater efficacy of TIO+OLO vs TIO in reducing exacerbations. They noted that both treatments were well tolerated.